TY - JOUR
T1 - Long-term outcomes of surgical menopause after risk-reducing salpingo-oophorectomy
T2 - results of the HARMOny study
AU - Beekman, Maarten J
AU - Terra, Lara
AU - Bleiker, Eveline M A
AU - Heemskerk-Gerritsen, Bernadette A M
AU - van Doorn, Helena C
AU - de Hullu, Joanne A
AU - van Dorst, Eleonora B L
AU - Mom, Constantijne H
AU - van Beurden, Marc
AU - Slangen, Brigitte F M
AU - Mourits, Marian J E
AU - Roeters van Lennep, Jeanine E
AU - Gaarenstroom, Katja N
AU - van Engelen, Klaartje
AU - van der Kolk, Lizet E
AU - Collée, J Margriet
AU - Wevers, Marijke R
AU - Ausems, Margreet G E M
AU - Berger, Lieke P V
AU - Gomez Garcia, Encarna B
AU - van Asperen, Christi J
AU - Maas, Angela H E M
AU - van Leeuwen, Flora E
AU - Hooning, Maartje J
N1 - Copyright © 2026 Elsevier B.V. All rights reserved.
PY - 2026/2/14
Y1 - 2026/2/14
N2 - BACKGROUND: Premenopausal risk-reducing salpingo-oophorectomy (RRSO), often performed for women at high familial risk of ovarian cancer, induces immediate menopause. Evidence about its long-term effects is scarce.METHODS: We conducted a cross-sectional study (n = 740) nested in a nationwide cohort of women at high familial risk of ovarian cancer. Participants completed a cognition test and a questionnaire on lifestyle, sexual functioning, urinary incontinence and health-related quality of life (HRQOL, SF-36). Cardiovascular disease (CVD) risk and bone mineral density (BMD) were assessed during a clinical visit. In women aged 60-70 years at study visit (n = 330), we compared potential long-term health effects of RRSO between women who underwent the procedure before menopause (i.e. when aged ≤45years) and those who had the procedure after menopause (when aged ≥54years).RESULTS: Participants' median age was 64.3 years, and the median time since premenopausal RRSO was 21 years. A comprehensive overview of our (partially published) results showed that a premenopausal RRSO compared with a postmenopausal RRSO was not associated with long-term coronary artery calcification, objective cognitive functioning, urinary incontinence or impaired health-related quality of life. However, women in the premenopausal RRSO group had lower bone mineral density and reported more vaginal dryness and sexual discomfort compared with the postmenopausal RRSO group.CONCLUSION: Premenopausal RRSO does not appear to be associated with long-term cardiovascular disease risk, cognition or health-related quality of life. However, it negatively influences bone mineral density and vaginal dryness.CLINICAL TRIAL REGISTRATION: Pre-registered clinical trial number: NCT03835793.
AB - BACKGROUND: Premenopausal risk-reducing salpingo-oophorectomy (RRSO), often performed for women at high familial risk of ovarian cancer, induces immediate menopause. Evidence about its long-term effects is scarce.METHODS: We conducted a cross-sectional study (n = 740) nested in a nationwide cohort of women at high familial risk of ovarian cancer. Participants completed a cognition test and a questionnaire on lifestyle, sexual functioning, urinary incontinence and health-related quality of life (HRQOL, SF-36). Cardiovascular disease (CVD) risk and bone mineral density (BMD) were assessed during a clinical visit. In women aged 60-70 years at study visit (n = 330), we compared potential long-term health effects of RRSO between women who underwent the procedure before menopause (i.e. when aged ≤45years) and those who had the procedure after menopause (when aged ≥54years).RESULTS: Participants' median age was 64.3 years, and the median time since premenopausal RRSO was 21 years. A comprehensive overview of our (partially published) results showed that a premenopausal RRSO compared with a postmenopausal RRSO was not associated with long-term coronary artery calcification, objective cognitive functioning, urinary incontinence or impaired health-related quality of life. However, women in the premenopausal RRSO group had lower bone mineral density and reported more vaginal dryness and sexual discomfort compared with the postmenopausal RRSO group.CONCLUSION: Premenopausal RRSO does not appear to be associated with long-term cardiovascular disease risk, cognition or health-related quality of life. However, it negatively influences bone mineral density and vaginal dryness.CLINICAL TRIAL REGISTRATION: Pre-registered clinical trial number: NCT03835793.
U2 - 10.1016/j.maturitas.2026.108882
DO - 10.1016/j.maturitas.2026.108882
M3 - Article
C2 - 41724092
SN - 0378-5122
VL - 207
JO - Maturitas
JF - Maturitas
M1 - 108882
ER -